Navigation Links
New research network at McMaster aims to build a better eye

Researchers in Canada have established a new university/industry network to pursue the development of biomaterials, medical devices and drug delivery systems to treat the increasing incidence of eye disease.

The 20/20: NSERC Ophthalmic Materials Network (20/20 Network) has received $5 million as part of the Natural Sciences and Engineering Research Council of Canada (NSERC) funding announcement made by federal Minister of State (Science and Technology) Gary Goodyear today at McMaster University in Hamilton. Other funding is being provided by industrial and institutional partners, and the Ontario Centres of Excellence.

"Providing Canadians with a lifetime of perfect vision is the ultimate goal of the network," said Heather Sheardown, scientific director of the 20/20 Network and professor of chemical engineering at McMaster University. "It is rather ambitious but by combining different areas of expertise there is a lot of potential for drastically improving treatment of vision loss."

The 20/20 Network will focus on developing and commercializing new biomaterials, medical devices, and drug delivery devices for treating vision disorders. Some of the products being pursued include: composite and hybrid materials; ocular microgels, microemulsions and triggerable materials for drug release; a drug delivery system that attaches to the back of the eye to eliminate monthly needle injections; and contact lenses that eliminate end-of-day dryness and discomfort.

"The potential for new biomaterials and drug-delivery devices to address vision loss is hugely untapped," said Keith Gordon, vice president research, CNIB and chair of the Board of Directors of the 20/20 Network. "This is the type of initiative we need to release our research talent in Canada, provide new therapies for vision loss, and develop a homegrown industry."

The 12 researchers in the network are from four Canadian universities: McMaster University, where the administrative centre will be based, Queen's University, University of Toronto, and the University of Waterloo.

The 10 industrial partners are: Alimera Sciences, CIBA Vision Corporation, Custom Contact Lenses, Fovea Pharmaceuticals, iCo Therapeutics, Rimon Therapeutics, Siltech Corporation, Take Control Cosmedix, Vista Optics Limited, and Walsh Medical Devices.

It is estimated that 30 to 40 post-doctoral fellows, 35 to 45 graduate students and more than 60 summer students will be trained through the network over the five-year funding period.

"There is a lot of innovative and promising work being done in universities to address disorders of the eye and other conditions," said Michael May, president, Rimon Therapeutics Ltd. and a member of the board of directors. "This network provides an ideal forum to bring key players together and move solutions into the market as quickly as possible."


Contact: Gene Nakonechny
905-525-9140 x26781
McMaster University

Related biology news :

1. WPI receives $1.3 million in federal awards for ongoing research in the life sciences
2. Stem cell applications and research highlight NJITs first Research Cafe
3. NIH announces 115 awards to encourage high-risk research and innovation
4. New genetic research indicates Jewish priesthood has multiple lineages
5. Prestigious $4.9 million NIH grant awarded to Case Western Reserve for colon cancer research
6. UNC scientists garner new NIH awards for high risk, transformative research
7. Researchers identify new brain pathway for regulating weight and bone mass
8. McGill garners 19 Canada Research Chairs and more than $17 million in funding
9. Research team finds first evolutionary branching for bilateral animals
10. 57 college presidents declare support for public access to publicly funded research in the US
11. Georgia State researcher to use $1 million grant to improve computer models for fighting wildfires
Post Your Comments:
(Date:11/17/2015)... , November 17, 2015 ... au 19 novembre  2015.  --> Paris ... --> DERMALOG, le leader de l,innovation biométrique, ... la fois passeports et empreintes sur la même surface ... les passeports et l,autre pour les empreintes digitales. Désormais, ...
(Date:11/12/2015)... BOSTON , Nov. 12, 2015  A golden ... for Duchenne muscular dystrophy (DMD) has provided a new ... Boston Children,s Hospital, the Broad Institute of MIT and ... Brazil . Cell, ... some dogs "escape" the disease,s effects. The Boston Children,s ...
(Date:11/10/2015)...  In this report, the biomarkers market ... type, application, disease indication, and geography. The ... consumables, services, software. The type segments included ... biomarkers, and validation biomarkers. The applications segments ... drug discovery and development, personalized medicine, disease ...
Breaking Biology News(10 mins):
(Date:11/24/2015)... Nov. 24, 2015 Halozyme Therapeutics, Inc. (NASDAQ: HALO ... New York on Wednesday, December 2 at ... , president and CEO, will provide a corporate overview. ... at 1:00 p.m. ET/10:00 a.m. PT . ... will provide a corporate overview. --> th Annual ...
(Date:11/24/2015)... 24, 2015  Clintrax Global, Inc., a worldwide provider of clinical ... today announced that the company has set a new quarterly earnings ... on quarter growth posted for Q3 of 2014 to Q3 of ... Mexico , with the establishment of an ... --> United Kingdom and Mexico ...
(Date:11/24/2015)... , November 24, 2015 ... recent market research report released by Transparency Market Research, ... expand at a CAGR of 17.5% during the period ... Testing Market - Global Industry Analysis, Size, Volume, Share, ... global non-invasive prenatal testing market to reach a valuation ...
(Date:11/24/2015)... ... 2015 , ... InSphero AG, the leading supplier of easy-to-use solutions for production, ... to serve as Chief Operating Officer. , Having joined InSphero in November ... and was promoted to Head of InSphero Diagnostics in 2014. There she has ...
Breaking Biology Technology: